Ng SS - Search Results

1

Antiangiogenesis therapeutic strategies in prostate cancer.

Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD. Macpherson GR, et al. Among authors: ng ss. Cancer Metastasis Rev. 2002;21(1):93-106. doi: 10.1023/a:1020128708223. Cancer Metastasis Rev. 2002. PMID: 12400998 Review.

2

Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice.

Ng SS, Figg WD. Ng SS, et al. Anticancer Res. 2003 Sep-Oct;23(5A):3585-90. Anticancer Res. 2003. PMID: 14666653

3

Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.

Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD. Macpherson GR, et al. Among authors: ng ss. Mol Cancer Ther. 2003 Sep;2(9):845-54. Mol Cancer Ther. 2003. PMID: 14555703

4

Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.

Ng SS, Figg WD, Sparreboom A. Ng SS, et al. Cancer Res. 2004 Feb 1;64(3):821-4. doi: 10.1158/0008-5472.can-03-3391. Cancer Res. 2004. PMID: 14871806

5

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.

Ng SS, MacPherson GR, Gütschow M, Eger K, Figg WD. Ng SS, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4192-7. doi: 10.1158/1078-0432.CCR-03-0700. Clin Cancer Res. 2004. PMID: 15217957

6

Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy.

Ng SS, Figg WD. Ng SS, et al. Cancer Biol Ther. 2004 Dec;3(12):1212-3. doi: 10.4161/cbt.3.12.1369. Epub 2004 Dec 15. Cancer Biol Ther. 2004. PMID: 15662130 Free article. Review.

7

Thalidomide, an antiangiogenic agent with clinical activity in cancer.

Ng SS, Brown M, Figg WD. Ng SS, et al. Biomed Pharmacother. 2002 Jun;56(4):194-9. doi: 10.1016/s0753-3322(02)00177-4. Biomed Pharmacother. 2002. PMID: 12109812 Review.

8

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.

Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Ng SS, et al. Cancer Res. 2003 Jun 15;63(12):3189-94. Cancer Res. 2003. PMID: 12810647

9

A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.

Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD. Tohnya TM, et al. Among authors: ng ss. Clin Prostate Cancer. 2004 Mar;2(4):241-3. doi: 10.3816/cgc.2004.n.006. Clin Prostate Cancer. 2004. PMID: 15072608 Clinical Trial. No abstract available.

10

Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.

Lepper ER, Ng SS, Gütschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD. Lepper ER, et al. Among authors: ng ss. J Med Chem. 2004 Apr 22;47(9):2219-27. doi: 10.1021/jm0304820. J Med Chem. 2004. PMID: 15084120

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

692 results

Search Page

Filters